Global collaboration announced to develop seralutinib for pulmonary hypertension
Chiesi Farmaceutici and Gossamer Bio Inc have entered into a global collaboration to develop seralutinib for pulmonary hypertension treatment.
Trial demonstrates ARM-002TM vaccine’s effectiveness against pancreatic cancer
Defence Therapeutics has announced a successful pre-clinical vaccination trial utilising its ARM-002TM vaccine against pancreatic cancer.
ARM-002TM anti-cancer vaccine shows promise in combatting pre-established melanoma
Defence Therapeutics Inc. has unveiled the exceptional efficacy of its second-generation ARMTM anti-cancer vaccine.
The anti-cancer vaccine, dubbed ARM-002TM, has demonstrated proficiency in combating pre-established...
Chiesi Group celebrates €3bn sales success in 2023
Chiesi Group, a renowned biopharmaceutical powerhouse headquartered in Parma, Italy, revealed €3bn in sales in 2023, a significant growth from the previous year.
With 31...
B Medical Systems’ TCW40SDD receives ACT label from My Green Lab
B Medical Systems, an industry leader in the medical cold chain sector, has received the prestigious ACT label from My Green Lab for its...
Time for Europe to prioritise preventative health
Vaccine confidence has fallen to pre-pandemic levels but, says Sibilia Quilici, Executive Director of Vaccines Europe, there is a need and value in boosting...
Defence Therapeutics announces successful ARM-002TM cancer vaccine results
Defence Therapeutics has announced the successful testing of its second-generation anti-cancer vaccine, named ARM-002TM, utilising its flagship anti-cancer molecule, AccuTOX®.
The ARM-002TM cancer vaccine, when...
Scientists pioneer new antimicrobial drugs from food by-products
Scientists are set to harness the potential of food by-products to manufacture antimicrobial drugs from bacteria.
AstraZeneca to invest £650m in UK’s life sciences sector
Pharmaceutical giant AstraZeneca has revealed plans to inject £650m into the UK, bolstering the nation's life sciences sector and propelling economic growth.
This significant investment...
Pharmaceutical pollution – the blue healthcare revolution
Dr Kelly Thornber, Post-Doctoral Research Fellow at the University of Exeter, discusses the key drivers of pharmaceutical pollution and its impact.
In 2020 the UK’s...
Defence Therapeutics granted US patent for AccuTOX® technology
Defence Therapeutics has achieved a significant milestone with the granting of US patent no. 11,890,350 ('350) by the United States Patent and Trademark Office...
Anti-diabetic drugs may lower brain cancer risk, says the University of Bristol
Researchers from the University of Bristol have uncovered a potential link between long-term use of certain anti-diabetic drugs and a reduced risk of primary...
NHS offers groundbreaking portable drug infusion for advanced Parkinson’s disease patients
Hundreds of NHS patients grappling with advanced Parkinson's disease are poised to experience relief thanks to a groundbreaking portable drug infusion set to revolutionise...
Tohoku University develops monoclonal antibody for HER2-positive breast cancer
Tohoku University have engineered a groundbreaking monoclonal antibody aimed at HER2-positive breast cancer.
The critical vaccine cold chain
Dr Nenad Miljković from the European Association of Hospital Pharmacists (EAHP) outlines the critical role of cold chain storage in maintaining the efficacy and...
Over 500,00 women access affordable hormone replacement therapy through HRT PPC
Over 500,000 women in England have accessed more affordable hormone replacement therapy (HRT), the primary treatment for menopause symptoms.
BioNxt acquires cutting-edge equipment to boost drug delivery product manufacturing
BioNxt Solutions Inc. has proudly announced the acquisition of advanced coating and cutting equipment, marking a crucial stride in expanding its commercial manufacturing of...
Defence Therapeutics’ breakthrough in cancer treatment: AccuTOX® shows promise against lung tumours
Defence Therapeutics has announced the successful testing of a new formulation of its ACCUM-002TM Dimer CDCA-SV40 against lung tumours.
Developing mRNA vaccine technology
Following the unprecedented development of vaccines during the COVID-19 pandemic, we spoke to Dinah Knotts about mRNA vaccine technology and what further opportunities it...
Defence Therapeutics granted FDA approval for Phase I Clinical Trial of AccuTOX®
Defence Therapeutics has announced a pivotal milestone: the U.S. Food and Drug Administration (FDA) has granted a green light with a "Study May Proceed"...
